OBJECTIVE: To correlate inflammatory cytokines and vascular endothelial growth factor (VEGF) in vitreous and plasma with vitreous retinol binding protein 3 (RBP3), diabetic retinopathy (DR) severity, and DR worsening in a population with type 1 and type 2 diabetes. RESEARCH DESIGN AND METHODS: RBP3, VEGF, and inflammatory cytokines were measured in plasma and vitreous samples (n = 205) from subjects of the Joslin Medalist Study and Beetham Eye Institute. RESULTS: Higher vitreous RBP3 concentrations were associated with less severe DR (P < 0.0001) and a reduced risk of developing proliferative DR (PDR) (P < 0.0001). Higher RBP3 correlated with increased photoreceptor segment thickness and lower vitreous interleukin-12 (IL-12), tumor necrosis factor-α (TNF-α), and TNF-β (P < 0.05). PDR was associated with lower vitreous interferon-γ and IL-10 and higher VEGF, IL-6, and IL-15 (P < 0.05), but was not associated with their plasma concentrations. CONCLUSIONS: Higher vitreous RBP3 concentrations are associated with less severe DR and slower rates of progression to PDR, supporting its potential as a biomarker and therapeutic agent for preventing DR worsening, possibly by lowering retinal VEGF and inflammatory cytokines.
OBJECTIVE: To correlate inflammatory cytokines and vascular endothelial growth factor (VEGF) in vitreous and plasma with vitreous retinol binding protein 3 (RBP3), diabetic retinopathy (DR) severity, and DR worsening in a population with type 1 and type 2 diabetes. RESEARCH DESIGN AND METHODS: RBP3, VEGF, and inflammatory cytokines were measured in plasma and vitreous samples (n = 205) from subjects of the Joslin Medalist Study and Beetham Eye Institute. RESULTS: Higher vitreous RBP3 concentrations were associated with less severe DR (P < 0.0001) and a reduced risk of developing proliferative DR (PDR) (P < 0.0001). Higher RBP3 correlated with increased photoreceptor segment thickness and lower vitreous interleukin-12 (IL-12), tumor necrosis factor-α (TNF-α), and TNF-β (P < 0.05). PDR was associated with lower vitreous interferon-γ and IL-10 and higher VEGF, IL-6, and IL-15 (P < 0.05), but was not associated with their plasma concentrations. CONCLUSIONS: Higher vitreous RBP3 concentrations are associated with less severe DR and slower rates of progression to PDR, supporting its potential as a biomarker and therapeutic agent for preventing DR worsening, possibly by lowering retinal VEGF and inflammatory cytokines.
Authors: Hisashi Yokomizo; Yasutaka Maeda; Kyoungmin Park; Allen C Clermont; Sonia L Hernandez; Ward Fickweiler; Qian Li; Chih-Hao Wang; Samantha M Paniagua; Fabricio Simao; Atsushi Ishikado; Bei Sun; I-Hsien Wu; Sayaka Katagiri; David M Pober; Liane J Tinsley; Robert L Avery; Edward P Feener; Timothy S Kern; Hillary A Keenan; Lloyd Paul Aiello; Jennifer K Sun; George L King Journal: Sci Transl Med Date: 2019-07-03 Impact factor: 17.956
Authors: M Garcia-Ramírez; C Hernández; M Villarroel; F Canals; M A Alonso; R Fortuny; L Masmiquel; A Navarro; J García-Arumí; R Simó Journal: Diabetologia Date: 2009-10-13 Impact factor: 10.122
Authors: Ward Fickweiler; Emily A Wolfson; Samantha M Paniagua; Marc Gregory Yu; Atif Adam; Vanessa Bahnam; Konstantina Sampani; I-Hsien Wu; Gail Musen; Lloyd P Aiello; Hetal Shah; Jennifer K Sun; George L King Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 5.958
Authors: Jan Lammer; Sonja G Prager; Michael C Cheney; Amel Ahmed; Salma H Radwan; Stephen A Burns; Paolo S Silva; Jennifer K Sun Journal: Invest Ophthalmol Vis Sci Date: 2016-12-01 Impact factor: 4.799